Elnara Marcia Negri

Elnara Marcia Negri

Auto-generated profile, based on publicly available information

Elnara Marcia Negri

Departamento de Patologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2020 in Frontiers in Physiology
Verified
Journal Article
Open access
PDF file
ENElnara Marcia Negri
Elnara Marcia Negri
BPBruna Mamprim Piloto
Bruna Mamprim Piloto
LMLuciana Kato Morinaga
Luciana Kato Morinaga
CJCarlos Viana Poyares Jardim
Carlos Viana Poyares Jardim
SLShari Anne El-Dash Lamy
Shari Anne El-Dash Lamy
DDDaniel Deheinzelin
Daniel Deheinzelin
Introduction: Elevated D-dimer is a predictor of severity and mortality in COVID-19 patients, and heparin use during in-hospital stay has been associated with decreased mortality. COVID-19 patient autopsies have revealed thrombi in the microvasculature, suggesting that hypercoagulability is a prominent feature of organ failure in these patients. Interestingly, in COVID-19, pulmonary compliance is preserved despite severe hypoxemia corroborating the hypothesis that perfusion mismatch may play a significant role in the development of respiratory failure. Methods: We describe a series of 27 consecutive COVID-19 patients admitted to Sirio-Libanes Hospital in São Paulo-Brazil and treated with heparin in therapeutic doses tailored to clinical severity. Results: PaO2/FiO2 ratio increased significantly over the 72 h following the start of anticoagulation, from 254(±90) to 325(±80), p = 0.013, and 92% of the patients were discharged home within a median time of 11 days. There were no bleeding complications or fatal events. Discussion: Even though this uncontrolled case series does not offer absolute proof that micro thrombosis in the pulmonary circulation is the underlying mechanism of respiratory failure in COVID-19, patient’s positive response to heparinization contributes to the understanding of the pathophysiological mechanism of the disease and provides valuable information for the treatment of these patients while we await the results of further prospective controlled studies.

17 December 2021 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MMMsc Michelle Sholzberg Mdcm
Msc Michelle Sholzberg Mdcm
BCBruno R. da Costa
Bruno R. da Costa
GMGrace H. Tang Msc
Grace H. Tang Msc
HRHassan Rahhal
Hassan Rahhal
MAMusaad AlHamzah
Musaad AlHamzah
TIthe RAPID Trial Investigators
the RAPID Trial Investigators
Background Pulmonary endothelial injury and microcirculatory thromboses likely contribute to hypoxemic respiratory failure, the most common cause of death, in patients with COVID-19. Randomized controlled trials (RCTs) suggest differences in the effect of therapeutic heparin between moderately and severely ill patients with COVID-19. We did a systematic review and meta-analysis of RCTs to determine the effects of therapeutic heparin in hospitalized patients with COVID-19. Methods We searched PubMed, Embase, Web of Science, medRxiv, and medical conference proceedings for RCTs comparing therapeutic heparin with usual care, excluding trials that used oral anticoagulation or intermediate doses of heparin in the experimental arm. Mantel-Haenszel fixed-effect meta-analysis was used to combine odds ratios (ORs). Results and Conclusions There were 3 RCTs that compared therapeutic heparin to lower doses of heparin in 2854 moderately ill ward patients, and 3 RCTs in 1191 severely ill patients receiving critical care. In moderately ill patients, there was a nonsignificant reduction in all-cause death (OR, 0.76; 95% CI, 0.57-1.02), but significant reductions in the composite of death or invasive mechanical ventilation (OR, 0.77; 95% CI, 0.60 0.98), and death or any thrombotic event (OR, 0.58; 95% CI, 0.45-0.77). Organ support-free days alive (OR, 1.29; 95% CI, 1.07-1.57) were significantly increased with therapeutic heparin. There was a nonsignificant increase in major bleeding. In severely ill patients, there was no evidence for benefit of therapeutic heparin, with significant treatment-by-subgroup interactions with illness severity for all-cause death (P = .034). In conclusion, therapeutic heparin is beneficial in moderately ill patients but not in severely ill patients hospitalized with COVID-19.

22 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
JLJuliana Dias Lourenço
Juliana Dias Lourenço
WTWalcy Rosolia Teodoro
Walcy Rosolia Teodoro
DBDenise F. Barbeiro
Denise F. Barbeiro
AVAna Paula Pereira Velosa
Ana Paula Pereira Velosa
LSLarissa E. F. Silva
Larissa E. F. Silva
FLFernanda Lopes
Fernanda Lopes
Th17/Treg imbalance plays a pivotal role in COPD development and progression. We aimed to assess Th17/Treg-related intracellular signaling at different COPD stages in local and systemic responses. Lung tissue and/or peripheral blood samples were collected and divided into non-obstructed (NOS), COPD stages I and II, and COPD stages III and IV groups. Gene expression of STAT3 and -5, RORγt, Foxp3, interleukin (IL)-6, -17, -10, and TGF-β was assessed by RT-qPCR. IL-6, -17, -10, and TGF-β levels were determined by ELISA. We observed increased STAT3, RORγt, Foxp3, IL-6, and TGF-β gene expression and IL-6 levels in the lungs of COPD I and II patients compared to those of NOS patients. Regarding the systemic response, we observed increased STAT3, RORγt, IL-6, and TGF-β gene expression in the COPD III and IV group and increased IL-6 levels in the COPD I and II group. STAT5 was increased in COPD III and IV patients, although there was a decrease in Foxp3 expression and IL-10 levels in the COPD I and II and COPD III and IV groups, respectively. We demonstrated that an increase in Th17 intracellular signaling in the lungs precedes this increase in the systemic response, whereas Treg intracellular signaling varies between the compartments analyzed in different COPD stages.

13 June 2014 in Malaria Journal
Verified
Journal Article
Open access
PDF file
EAElizabeth H Aitken
Elizabeth H Aitken
ENElnara M Negri
Elnara M Negri
RBRenato Barboza
Renato Barboza
MLMaria Ri Lima
Maria Ri Lima
JÁJosé M Álvarez
José M Álvarez
SESabrina Epiphanio
Sabrina Epiphanio
The mechanisms through which infection with Plasmodium spp. result in lung disease are largely unknown. Recently a number of mouse models have been developed to research malaria-associated lung injury but no detailed ultrastructure studies of the disease in its terminal stages in a murine model have yet been published. The goal was to perform an ultrastructural analysis of the lungs of mice that died with malaria-associated acute lung injury/acute respiratory distress syndrome to better determine the relevancy of the murine models and investigate the mechanism of disease.

10 March 2021 in Trials
Verified
Journal Article
Open access
PDF file
MSMichelle Sholzberg
Michelle Sholzberg
GTGrace H. Tang
Grace H. Tang
ENElnara Negri
Elnara Negri
HRHassan Rahhal
Hassan Rahhal
LKLisa Baumann Kreuziger
Lisa Baumann Kreuziger
PJPeter Jüni
Peter Jüni
Objectives: To determine the effect of therapeutic anticoagulation, with low molecular weight heparin (LMWH) or unfractionated heparin (UFH, high dose nomogram), compared to standard care in hospitalized patients admitted for COVID-19 with an elevated D-dimer on the composite outcome of intensive care unit (ICU) admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death up to 28 days. Trial design: Open-label, parallel, 1:1, phase 3, 2-arm randomized controlled trial Participants: The study population includes hospitalized adults admitted for COVID-19 prior to the development of critical illness. Excluded individuals are those where the bleeding risk or risk of transfusion would generally be considered unacceptable, those already therapeutically anticoagulated and those who have already have any component of the primary composite outcome. Participants are recruited from hospital sites in Brazil, Canada, Ireland, Saudi Arabia, United Arab Emirates, and the United States of America. The inclusion criteria are: Laboratory confirmed COVID-19 (diagnosis of SARS-CoV-2 via reverse transcriptase polymerase chain reaction as per the World Health Organization protocol or by nucleic acid based isothermal amplification) prior to hospital admission OR within first 5 days (i.e. 120 hours) after hospital admission; Admitted to hospital for COVID-19; One D-dimer value above the upper limit of normal (ULN) (within 5 days (i.e. 120 hours) of hospital admission) AND EITHER: D-Dimer ≥2 times ULN OR D-Dimer above ULN and Oxygen saturation ≤ 93% on room air; > 18 years of age; Informed consent from the patient (or legally authorized substitute decision maker). The exclusion criteria are: pregnancy; hemoglobin <80 g/L in the last 72 hours; platelet count <50 x 109/L in the last 72 hours; known fibrinogen <1.5 g/L (if testing deemed clinically indicated by the treating physician prior to the initiation of anticoagulation); known INR >1.8 (if testing deemed clinically indicated by the treating physician prior to the initiation of anticoagulation); patient already prescribed intermediate dosing of LMWH that cannot be changed (determination of what constitutes an intermediate dose is to be at the discretion of the treating clinician taking the local institutional thromboprophylaxis protocol for high risk patients into consideration); patient already prescribed therapeutic anticoagulation at the time of screening [low or high dose nomogram UFH, LMWH, warfarin, direct oral anticoagulant (any dose of dabigatran, apixaban, rivaroxaban, edoxaban)]; patient prescribed dual antiplatelet therapy, when one of the agents cannot be stopped safely; known bleeding within the last 30 days requiring emergency room presentation or hospitalization; known history of a bleeding disorder of an inherited or active acquired bleeding disorder; known history of heparin-induced thrombocytopenia; known allergy to UFH or LMWH; admitted to the intensive care unit at the time of screening; treated with non-invasive positive pressure ventilation or invasive mechanical ventilation at the time of screening; Imminent death according to the judgement of the most responsible physician; enrollment in another clinical trial of antithrombotic therapy involving hospitalized patients. Intervention and comparator: Intervention: Therapeutic dose of LMWH (dalteparin, enoxaparin, tinzaparin) or high dose nomogram of UFH. The choice of LMWH versus UFH will be at the clinician’s discretion and dependent on local institutional supply. Comparator: Standard care [thromboprophylactic doses of LMWH (dalteparin, enoxaparin, tinzaparin, fondaparinux)] or UFH. Administration of LMWH, UFH or fondaparinux at thromboprophylactic doses for acutely ill hospitalized medical patients, in the absence of contraindication, is generally considered standard care. Main outcomes: The primary composite outcome of ICU admission, non-invasive positive pressure ventilation, invasive mechanical ventilation or death at 28 days. Secondary outcomes include (evaluated up to day 28): All-cause death Composite of ICU admission or all-cause death Composite of mechanical ventilation or all-cause death Major bleeding as defined by the ISTH Scientific and Standardization Committee (ISTH-SSC) recommendation; Red blood cell transfusion (>1 unit); Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate; Renal replacement therapy; Hospital-free days alive; ICU-free days alive; Ventilator-free days alive; Organ support-free days alive; Venous thromboembolism (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate); Arterial thromboembolism (defined as suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate); Heparin induced thrombocytopenia; Trajectories of COVID-19 disease-related coagulation and inflammatory biomarkers. Randomisation: Randomisation will be stratified by site and age (>65 versus ≤65 years) using a 1:1 computer-generated random allocation sequence with variable block sizes. Randomization will occur within the first 5 days (i.e. 120 hours) of participant hospital admission. However, it is recommended that randomization occurs as early as possible after hospital admission. Central randomization using an interactive web response system will ensure allocation concealment. Blinding (masking): No blinding involved. This is an open-label trial. Numbers to be randomised (sample size): 462 patients (231 per group) are needed to detect a 15% risk difference, from 50% in the control group to 35% in the experimental group, with power of 90% at a two-sided alpha of 0.05. Trial Status: Protocol Version Number 1.4. Recruitment began on May 11th, 2020. Recruitment is expected to be completed March 2022. Recruitment is ongoing. Trial registration: ClinicalTrials.gov Identifier: NCT04362085 Date of Trial Registration: April 24, 2020 Full protocol: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

1 August 2021 in Estudos Avançados
Verified
Journal Article
Open access
AMAna Paula Garcia Martins
Ana Paula Garcia Martins
ARAndreza Portella Ribeiro
Andreza Portella Ribeiro
Maurício Lamano FerreiraMaurício Lamano Ferreira
Maurício Lamano Ferreira
MMMarco Martins
Marco Martins
ENElnara M. Negri
Elnara M. Negri
Raffaele LafortezzaRaffaele Lafortezza
Raffaele Lafortezza
RESUMO O Material Particulado (MP) está entre os principais contaminantes do ar. A Infraestrutura Verde (IV) vem sendo reconhecida como alternativa para melhorar a qualidade do ar. As árvores podem afetar diretamente os níveis de MP, interceptando partículas em sua superfície. Devido a essa capacidade, esta pesquisa teve como objetivo contribuir com informações sobre a viabilidade da vegetação verde para interceptar e identificar as principais fontes de poluentes atmosféricos. Amostras de cascas de árvores de parques urbanos de São Paulo (SP) foram utilizadas como monitor biológico de poluentes atmosféricos. Foi observado um decaimento exponencial das concentrações e aprisionamento de poluentes em direção à região mais interna dos parques. Além disso, foi possível distinguir a emissão de veículos leves das emissões de veículos pesados. O baixo custo do monitoramento e sua eficácia mostram que a IV ocupa papel de destaque na melhoria da saúde e a qualidade de vida das pessoas, bem como nas ações que buscam atenuar os efeitos da poluição do ar em cidades de médio e grande porte.